xRead - Olfactory Disorders (September 2023)

20426984, 2020, 7, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.22576 by University Of Chicago Library, Wiley Online Library on [25/07/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

Biologics on CRSwNP-induced olfactory dysfunction

FIGURE2. Risk of bias of individual RCTs and overall risk of bias of RCTs. RCT = randomized, controlled trial. compared with placebo (data not available). 17 The lack of data available in these 2 RCTs did not allow us to conduct a qualitative synthesis.

trend toward significance in the study by Gevaert et al. 16 According to Bachert et al, although a positive trend for olfaction was obvious quite early (week 9), a clear, statis tically significant difference was obvious only at the end of the study period (week 25). 19 Gevaert et al found that improved olfaction was sustained throughout the follow up period (11 months after the first dose), unlike the other symptoms, which returned to their previous levels after a

Mepolizumab Mepolizumab had a positive effect on olfaction in both included studies, 16,19 with a clear statistically significant improvement in the study by Bachert et al, 19 but only a

International Forum of Allergy & Rhinology, Vol. 10, No. 7, July 2020

897